+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 22 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.

Age: 18Years +All GendersPhase 3
209 locations
E

Actively Recruiting

Researchers are studying the effects and safety of petrelintide compared with a placebo in adults who are overweight or have obesity, with at least one related health condition but without Type 2 Diabetes. This Phase III trial aims to assess how petrelintide, combined with a reduced-calorie diet and increased physical activity, supports weight management over time. Participants will receive either petrelintide or a matching placebo through weekly subcutaneous injections using a drug-device combination. The study lasts 64 weeks, during which all participants will follow a calorie-restricted diet and increase physical activity. The trial uses a randomized, double-blind design to compare the outcomes between the two groups. Throughout the study, participants will be regularly assessed for changes in body weight, waist circumference, blood markers like cholesterol and glucose, blood pressure, quality of life, and physical functioning. Safety will be monitored by tracking adverse events and immune responses. The main focus is the percentage change in body weight from the start to week 64. Participants involvement includes periodic visits for evaluations, questionnaires, and health measurements to monitor progress and safety.

Age: 18Years +All GendersPhase 3
3 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of petrelintide compared to a placebo in adults who have overweight or obesity along with established cardiovascular disease. This Phase III study aims to understand how petrelintide, combined with a reduced-calorie diet and increased physical activity, may help manage weight in this population. Participants will receive either petrelintide or a matching placebo, both given as weekly subcutaneous injections using a drug-device combination product. The study follows a randomized, double-blind, placebo-controlled, parallel-group design, with treatment continuing up to 64 weeks. Both groups will also follow a reduced-calorie diet and increase physical activity during the trial. Throughout the study, participants will undergo regular assessments including measurements of body weight, waist circumference, blood tests for cholesterol and glucose levels, as well as questionnaires on quality of life and physical functioning. Researchers will monitor changes from baseline to week 64 and track any adverse events. The total participation duration spans the 64-week treatment period with ongoing monitoring of safety and effectiveness measures.

Age: 40Years +All GendersPhase 3
3 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, tolerability, and how the body processes LY4213663 in healthy adults and adults with rheumatoid arthritis RA. This Phase 1 study aims to understand potential side effects and how the drug behaves when given by injection under the skin or into a vein. The study includes both healthy participants and those diagnosed with RA, with a focus on basic science aspects of the treatment. The study involves several parts single-ascending doses a gradually increasing dose and multiple-ascending doses of LY4213663 or placebo given either subcutaneously or intravenously in healthy participants. In participants with RA, multiple doses of LY4213663 are given by these two methods. The study design includes randomized assignments to drug or placebo groups for the healthy participant parts, while the RA participant parts are open-label. The entire study lasts about 33 weeks, excluding screening. Participants will have blood tests to check drug levels and effects, as well as monitoring for any serious side effects related to the drug. Researchers will assess safety throughout the study by tracking adverse events. The study measures how much LY4213663 is in the blood over time and its maximum concentration. Participants will attend regular visits for dosing and assessments during the study period, which runs from screening through to the last follow-up around 33 weeks after dosing begins.

Age: 18Years - 75YearsAll GendersPhase 1
10 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of orforglipron in adults with overweight who are at risk of developing obesity-related complications such as type 2 diabetes, hypertension, and dyslipidemia, or progressing to class 1 obesity. The study is a phase 3, randomized, double-blind, placebo-controlled trial that aims to understand whether this oral medication can reduce these risks over a two-year period. Participants will be randomly assigned to one of three groups receiving orforglipron orally throughout, orforglipron followed by placebo, or placebo followed by orforglipron. The study involves daily oral administration of these medications. The trial includes a long-term treatment period lasting up to 104 weeks about two years, during which participants are monitored for weight changes and the onset of obesity-related health issues. Throughout the study, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood markers like glycated hemoglobin and triglycerides, and quality of life questionnaires. Researchers will also monitor the time to onset of obesity-related complications and pharmacokinetics of orforglipron at specified intervals. Safety and effectiveness will be tracked continuously, with the primary outcome being the time until the development of obesity-related complications or progression to class 1 obesity.

Age: 18Years +All GendersPhase 3
180 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how ulonivirine MK-8507 affects the way methadone is processed in the body. This study involves healthy volunteers who are already participating in a methadone maintenance program. The purpose is to understand if taking ulonivirine with methadone changes the levels or activity of methadone in the body. Participants will take a stable oral dose of methadone daily from 14 days before the study starts through Day 16. On Day 2, participants will receive a single oral dose of ulonivirine together with methadone. The study observes the effects of this combination over this period to assess how ulonivirine impacts methadones presence in the body. During the study, participants will be monitored for up to 24 hours after dosing to measure methadone levels in the blood. Researchers will track various measures such as the amount of methadone in the plasma over time, peak concentrations, and time to peak concentration. Safety is also monitored by recording any adverse events during the 16-day study period. Participants will be required to attend study visits for dosing and assessments during this time.

Age: 18Years - 65YearsAll GendersPhase 1
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an investigational mRNA seasonal flu vaccine compared to a licensed flu vaccine in adults aged 65 years and older. The study aims to assess the ability of the vaccines to prevent laboratory-confirmed influenza illness, monitor side effects, and measure immune responses during the flu season. This Phase 3 randomized, observer-blind trial is sponsored by GlaxoSmithKline and focuses on flu prevention in older adults. Participants will receive a single injection on Day 1 of either the investigational mRNA seasonal flu vaccine or a licensed, age-appropriate, season-adapted influenza vaccine. The study follows a parallel group design where participants are randomly assigned to one of these two vaccine groups. The follow-up period covers the entire influenza season to assess vaccine efficacy and safety. During the study, participants will be monitored for influenza-like illness confirmed by laboratory tests from Day 15 through the end of the influenza season. Safety assessments include tracking solicited local and systemic side effects from Day 1 to Day 7, unsolicited adverse events up to Day 28, and serious adverse events or special interest adverse events through at least 180 days of follow-up. Blood samples will be collected before dosing and on Day 29 to evaluate immune responses. Participants are followed for safety and efficacy throughout the flu season, with total involvement spanning several months.

Age: 65Years +All GendersPhase 3
163 locations
P

Actively Recruiting

Researchers are evaluating a new mRNA vaccine that combines protection against both seasonal flu and COVID-19 in healthy adults aged 65 to 85 years. This early-stage Phase 1 study aims to assess the safety and immune response of this investigational vaccine compared to standard licensed flu and COVID-19 vaccines. The study is focused on measuring side effects and how well the vaccine builds protection against both infections. Participants will receive a single intramuscular injection of either one of three dose levels of the investigational mRNA combination vaccine, a licensed seasonal flu vaccine, or a licensed COVID-19 vaccine. The study groups are randomized and observer-blind. The investigational vaccine is given as a single dose, with three different dosage levels being tested sequentially for safety and immune response. During the study, participants will be monitored for side effects from the day of vaccination through several time points up to 181 days. Blood samples will be collected at specified intervals to evaluate immune responses against flu and COVID-19. The main measures include the number of participants experiencing laboratory abnormalities and adverse events, as well as immune protection markers such as antibody levels and seroconversion rates. The total participation spans from vaccination day through about six months of follow-up.

Age: 65Years - 85YearsAll GendersPhase 1
12 locations
S

Actively Recruiting

Researchers are studying the effects of ABBV-519 in adults with Systemic Lupus Erythematosus SLE or Rheumatoid Arthritis RA, two chronic autoimmune diseases. This phase 1 trial aims to understand how ABBV-519 moves through the body, its safety, and its effects on immune cells in people with moderate SLE or RA. The study is led by AbbVie and involves about 30 participants. Participants will receive a single dose of ABBV-519 either as an intravenous IV infusion or a subcutaneous SC injection. The study is designed as a single ascending dose trial with multiple dosing groups. The total study period spans approximately 425 days, including a 60-day screening period, a 1-day treatment administration, and a 52-week follow-up after dosing. Throughout the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor treatment effects and potential side effects. Researchers will measure changes in blood B cell counts and pharmacokinetic parameters such as drug concentration over time. Safety will be closely monitored for adverse events during the entire study period.

Age: 18Years - 75YearsAll GendersPhase 1
15 locations
E

Actively Recruiting

Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.

Age: 12Years +All GendersPhase 3
185 locations

1-10 of 22

1